Decreased miR-218–5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer
Oncology Research and Treatment · 2019 · 42 (4) · 165-181
DOI: 10.1159/000495473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, online erschienen am 14.03.2019. Verfasst von Peng Peng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Zhuhai Second People's Hospital, Zhuhai, China. Hauptthemen laut MEDLINE: Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Background: miR-218–5p is an extensively studied microRNA (miRNA) in prostate cancer (PCa). However, the clinical significance and biological role of miR-218–5p in bone metastasis of PCa remain unclear. Materials and Methods: miR-218–5p expression was evaluated in 38 bone metastatic and 115 non-bone metastatic PCa tissues and serum samples. Clinical correlation of miR-218–5p expression with clinicopathological characteristics was analyzed. The biological roles of miR-218–5p in bone metastasis of PCa were investigated in vitro by invasion and migration assays. Bioinformatics analysis, real-time polymerase chain reaction, western blot, and luciferase reporter assay were applied to discern and examine the relationship between miR-218–5p and its potential targets. Results: miR-218–5p expression was reduced in bone metastatic PCa tissue and serum samples, which positively correlated with poor clinicopathological characteristics and bone metastasis-free survival in PCa patients. Upregulating miR-218–5p repressed PCa cell invasion and migration. Furthermore, miR-218–5p inhibited NF-κB signaling via simultaneously targeting TRAF1, TRAF2, and TRAF5, which suppressed the invasion and migration abilities of PCa cells. ROC curve analysis of miR-218–5p in the serum of PCa patients exhibited an area under the curve of 0.86 (95% confidence interval 0.80–0.92, p < 0.001). Conclusion: Our findings indicate that miR-218–5p might represent a novel serum biomarker for bone metastasis of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Zhuhai Second People's Hospital, Zhuhai, China.
- Department of Orthopedic Surgery, The Fifth Hospital Affiliated of Sun Yat-sen University, Zhuhai, China.
- Department of Orthopedic Surgery, The Affiliated Hospital of Zunyi Medical College, Zunyi, China.
- Department of Ophthalmology, Zhuhai Second People's Hospital, Zhuhai, China.
- Department of Pediatrics, The Fifth Hospital Affiliated of Sun Yat-sen University, Zhuhai, China.
- Department of Orthopedic Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zitieren
APA
Peng, P., Chen, T., Wang, Q., Zhang, Y., Zheng, F., Huang, S., Tang, Y., Yang, C., Ding, W., Ren, D., Huang, Z., & Guo, Y. (2019). Decreased miR-218–5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer. Oncology Research and Treatment, 42(4), 165-181. https://doi.org/10.1159/000495473
Vancouver
Peng P, Chen T, Wang Q, Zhang Y, Zheng F, Huang S, et al. Decreased miR-218–5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer. Oncology Research and Treatment. 2019;42(4):165-181. doi:10.1159/000495473
BibTeX
@article{Peng2019,
author = {Peng, Peng and Chen, Tao and Wang, Qing and Zhang, Yixi and Zheng, Fangfang and Huang, Shuai and Tang, Yubo and Yang, Chunxiao and Ding, Wenqing and Ren, Dong and Huang, Zongwen and Guo, Yuanqing},
title = {Decreased miR-218–5p Levels as a Serum Biomarker in Bone Metastasis of Prostate Cancer},
journal = {Oncology Research and Treatment},
year = {2019},
volume = {42},
number = {4},
pages = {165--181},
doi = {10.1159/000495473}
}
EUVIMED